JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Cross-reactivity between Borrelia burgdorferi and "arthrogenic" bacteria in sera from patients with reactive arthritis.

The occurrence of specific antibodies for "arthrogenic bacteria" and Borrelia burgdorferi was analysed in sera samples from 30 patients with reactive arthritis. The control group consisted of 30 healthy blood donors. Our data showed that 66.6% (20) of the 30 examined patients had positive tests for Borrelia burgdorferi antigens and of all the patients, most of them (85%) had increased antibody levels against Salmonella antigens, 30% had increased levels of antibodies against Shigella antigens and 10% had antibodies for Yersinia antigens. Our findings indicated that the presence of antibodies to Borrelia burgdorferi and "arthrogenic enteric bacteria" in sera samples of patients with REA is evidence of wide cross-reactivity between these microorganisms.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app